¡¡
  • Product information --KH901

Individualized tumor vaccine --Comfeagen£¨KH901£©£»

 

The KH901 is a kind of treatment type tumor vaccine. Through maneuver of patient body immunity response, it then kills tumor cell. It has repression function of individualized treatment type tumor vaccine of distant tumor organization and can repress tumor cell transference. Pre-clinic experiment has already proven that KH901 is effective to various solid tumors. In the treatment of tumor, bringing forth a brand new way; it leads in domestic and international tumor curing.

 

 

  • Product information --KH902

     Ophthalmologic genetic engineering pharmacy --Fumintide£¨KH902£©

The KH902 is a kind of antibody medicine. It promotes efficiently blood vessel growth factor combination, and represses fresh pathological change of blood vessel growth. It can be used for curing various eye bottom disease causes by new-born pathological changes of blood vessel growth, such as aging related yellow spot change, diabetes retina pathological changes and cornea transplantation pathological changes etc. Recent research proven that, in curing aging related yellow spot change, KH902 activity is 100 times superior  to Lucentis, a United States market new medicine. The Kanghong Biotechnology Co. Ltd. owns independent intelligent property right of the KH902 and its related technique.

 

  • Product information --KH903

     Tumor genetic engineering pharmacy ?Vastatin (KH903)

The KH903 is a kind of targeted antibody medicine. It combines specially and efficiently with blood vessel growth factor, repressing tumor blood vessel formation and nutrient supply, aiming at killing tumor. Animal model experiment has shown that KH903 is effective to most solid tumors, including enteroncus, breast cancer hepatoma, lung tumor, encephaloma and stomach tumor etc. One thing worth mentioning is that, compared with similar United States anti-tumor medicine Avastin (developed by ROCHE and GENENTECH), anti-tumor activity of KH903 is 50-100 times higher. The Kanghong Biotechnology Co. Ltd. owns independent intelligent property right of the KH903 and its related technique.